{"schema_version":"secwatch.filing_event.v1","accession":"0001093557-24-000179","form_type":"8-K","ticker":"DXCM","cik":"0001093557","company_name":"DEXCOM INC","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.639978+00:00","generated_at":"2026-05-30T10:20:02.270870+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Dexcom Q3 revenue $994M (+2%); reiterates FY24 guidance; CCO retiring","bullets":["Revenue $994.2M (+2% reported, +3% organic); U.S. down 2%, international up 12%.","GAAP net income $134.6M ($0.34 EPS); Non-GAAP $179.9M ($0.45 EPS). Operating margin contracted.","Launched Stelo OTC glucose biosensor in U.S.; Dexcom G7 in Australia, ONE+ in France.","FY24 guidance reaffirmed: revenue ~$4.00-4.05B, non-GAAP operating margin ~20%.","Teri Lawver, EVP & Chief Commercial Officer, retiring year-end; CEO Sayer leading commercial while search ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001093557-24-000179","json":"https://secwatch.observer/filing/0001093557-24-000179.json","markdown":"https://secwatch.observer/filing/0001093557-24-000179.md","text":"https://secwatch.observer/filing/0001093557-24-000179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1093557/000109355724000179/0001093557-24-000179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1093557/000109355724000179/dxcm-20241024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:20:02.270870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}